Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 12—December 2021
CME ACTIVITY - Research

Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong

Cosmos L.T. Guo1, Thomas N.Y. Kwong1, Joyce W.Y. Mak, Lin Zhang, Grace C.Y. Lui, Grace L.H. Wong, Margaret Ip, Jun Yu, Joseph J.Y. Sung, William K.K. Wu2, and Sunny H. Wong2Comments to Author 
Author affiliations: The Chinese University of Hong Kong, Hong Kong, China (C.L.T. Guo, T.N.Y. Kwong, J.W.Y. Mak, L. Zhang, G.C.Y. Lui, G.L.H. Wong, M. Ip, J. Yu, J.J.Y. Sung, W.K.K. Wu, S.H. Wong); Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (J.J.Y. Sung, S.H. Wong)

Main Article

Figure

Clostridioides difficile infections in adults, Hong Kong, 2006–2019. Data for 2006–2014 were acquired from a previous study (13). A) Crude incidence of healthcare-associated and community-associated C. difficile infections. B) Incidence of infections by age group.

Figure. Clostridioides difficile infections in adults, Hong Kong, 2006–2019. Data for 2006–2014 were acquired from a previous study (13). A) Crude incidence of healthcare-associated and community-associated C. difficile infections. B) Incidence of infections by age group.

Main Article

References
  1. Leffler  DA, Lamont  JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–48. DOIPubMedGoogle Scholar
  2. Guh  AY, Mu  Y, Winston  LG, Johnston  H, Olson  D, Farley  MM, et al.; Emerging Infections Program Clostridioides difficile Infection Working Group. Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382:1320–30. DOIPubMedGoogle Scholar
  3. Heimann  SM, Cruz Aguilar  MR, Mellinghof  S, Vehreschild  MJGT. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48:23–9. DOIPubMedGoogle Scholar
  4. Rizzardi  K, Norén  T, Aspevall  O, Mäkitalo  B, Toepfer  M, Johansson  Å, et al. National surveillance for Clostridioides difficile infection, Sweden, 2009–2016. Emerg Infect Dis. 2018;24:1617–25. DOIPubMedGoogle Scholar
  5. Ofori  E, Ramai  D, Dhawan  M, Mustafa  F, Gasperino  J, Reddy  M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J Hosp Infect. 2018;99:436–42. DOIPubMedGoogle Scholar
  6. Valiente  E, Cairns  MD, Wren  BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect. 2014;20:396–404. DOIPubMedGoogle Scholar
  7. Collins  DA, Sohn  KM, Wu  Y, Ouchi  K, Ishii  Y, Elliott  B, et al.; Clostridioides difficile Asia-Pacific Study Group. Clostridioides difficile infection in the Asia-Pacific region. Emerg Microbes Infect. 2019;9:42–52. DOIPubMedGoogle Scholar
  8. Imwattana  K, Knight  DR, Kullin  B, Collins  DA, Putsathit  P, Kiratisin  P, et al. Clostridium difficile ribotype 017 - characterization, evolution and epidemiology of the dominant strain in Asia. Emerg Microbes Infect. 2019;8:796–807. DOIPubMedGoogle Scholar
  9. Collins  DA, Riley  TV. Clostridium difficile in Asia: opportunities for One Health management. Trop Med Infect Dis. 2018;4:E7. DOIPubMedGoogle Scholar
  10. Kong  KY, Kwong  TNY, Chan  H, Wong  K, Wong  SSY, Chaparala  AP, et al. Biological characteristics associated with virulence in Clostridioides difficile ribotype 002 in Hong Kong. Emerg Microbes Infect. 2020;9:631–8. DOIPubMedGoogle Scholar
  11. Wong  SH, Ip  M, Hawkey  PM, Lo  N, Hardy  K, Manzoor  S, et al. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong. J Infect. 2016;73:115–22. DOIPubMedGoogle Scholar
  12. Chow  VCY, Kwong  TNY, So  EWM, Ho  YII, Wong  SH, Lai  RWM, et al. Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong. Sci Rep. 2017;7:17218. DOIPubMedGoogle Scholar
  13. Ho  J, Dai  RZW, Kwong  TNY, Wang  X, Zhang  L, Ip  M, et al. Disease burden of Clostridium difficile infections in adults, Hong Kong, China, 2006–2014. Emerg Infect Dis. 2017;23:1671–9. DOIPubMedGoogle Scholar
  14. Sundararajan  V, Henderson  T, Perry  C, Muggivan  A, Quan  H, Ghali  WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94. DOIPubMedGoogle Scholar
  15. Cohen  SH, Gerding  DN, Johnson  S, Kelly  CP, Loo  VG, McDonald  LC, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55. DOIPubMedGoogle Scholar
  16. Thelwall  S, Nsonwu  O, Rooney  G, Wasti  S, Anselmo  J, Hope  R; Public Health England. Clostridium difficile infection: mandatory surveillance 2017/18. London: Public Health England; 2018.
  17. Wilcox  MH. Clostridium difficile surveillance in England. Infectious Agents Surveillance Report. 2020;41:39–41.
  18. US Centers for Disease Control and Prevention. 2017 annual report for the Emerging Infections Program for Clostridioides difficile infection. 2017 [cited 2021 Oct 15]. https://www.cdc.gov/hai/eip/pdf/cdiff/2017-CDI-Report-H.pdf
  19. Liao  F, Li  W, Gu  W, Zhang  W, Liu  X, Fu  X, et al. A retrospective study of community-acquired Clostridium difficile infection in southwest China. Sci Rep. 2018;8:3992. DOIPubMedGoogle Scholar
  20. Tariq  R, Cho  J, Kapoor  S, Orenstein  R, Singh  S, Pardi  DS, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis. 2018;66:514–22. DOIPubMedGoogle Scholar
  21. Ho  P, Wu  T, Chao  DV, Hung  IF, Lui  L, Lung  DC, et al. Reducing bacterial resistance with IMPACT, 5th edition, Hong Kong. Hong Kong: Centre for Health Protection—Department of Health; 2017.
  22. Lui  RN, Wong  SH, Lau  LHS, Chan  TT, Cheung  KCY, Li  A, et al. Faecal microbiota transplantation for treatment of recurrent or refractory Clostridioides difficile infection in Hong Kong. Hong Kong Med J. 2019;25:178–82.PubMedGoogle Scholar
  23. Gupta  A, Khanna  S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.PubMedGoogle Scholar
  24. Ng  SC, Leung  WK, Shi  HY, Li  MK, Leung  CM, Ng  CK, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016;22:1954–60. DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this work.

2These authors were co–principal investigators.

Page created: November 17, 2021
Page updated: November 17, 2021
Page reviewed: November 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external